Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrrolidine Maleate and Capecitabine Combined With Brain Radiotherapy in HER2-positive Breast Cancer Brain Metastases
NCT04767828Phase 4Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2020
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Time of intracranial tumor progression at 1 year. Status: unknown.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04767828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767828.